Arl2-Mediated Allosteric Release of Farnesylated KRas4B from Shuttling Factor PDEδ

E Sila Ozdemir, Hyunbum Jang1, Attila Gursoy

  • 1Cancer and Inflammation Program , Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, National Cancer Institute at Frederick , Frederick , Maryland 21702 , United States.

Insights

Arf-like protein 2 (Arl2) releases KRas4B from the PDEδ shuttling protein by inducing allosteric changes in PDEδ. This mechanism, revealed by molecular dynamics simulations, could guide the development of new cancer drugs targeting Ras proteins.

Area of Science:

  • Molecular biology
  • Cellular signaling
  • Biophysics

Background:

  • Ras proteins, particularly KRas4B, require precise plasma membrane (PM) localization for their signaling functions.
  • KRas4B and other Ras proteins interact with the PDEδ shuttling protein via their farnesylated hypervariable regions (HVRs) for transport to the PM.
  • Arf-like protein 2 (Arl2) is known to facilitate Ras release from PDEδ at the PM, but the underlying mechanism remains elusive.

Purpose of the Study:

  • To elucidate the detailed molecular mechanism by which Arl2 mediates the release of KRas4B from PDEδ.
  • To investigate the role of allosteric changes in PDEδ upon Arl2 binding.
  • To provide a mechanistic basis for potential therapeutic strategies targeting KRas4B.

Main Methods:

  • All-atom molecular dynamics simulations of ternary Arl2-PDEδ-KRas4B HVR complexes.
  • Analysis of structural changes and interactions within the simulated complexes.
  • Site-directed mutagenesis of key PDEδ residues to assess their role in the release process.

Main Results:

  • Arl2 binding to PDEδ weakens the interaction with the farnesylated KRas4B HVR.
  • Allosteric conformational changes in PDEδ, involving the β6 strand and other residues, lead to compression of the hydrophobic pocket, expelling the HVR.
  • Mutations in PDEδ residues critical for these allosteric changes abolish the release of KRas4B.

Conclusions:

  • The study reveals a precise allosteric mechanism for Arl2-mediated release of KRas4B from PDEδ.
  • Understanding this mechanism is crucial as mutant Ras proteins are prevalent in cancers.
  • The findings may inform the development of novel therapeutics aimed at inhibiting oncogenic KRas4B signaling by interfering with its release from PDEδ.

Related Concept Videos

Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.8K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

2.7K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

3.1K
Receptor-mediated Endocytosis01:39

Receptor-mediated Endocytosis

Overview
111.1K
Allosteric Regulation01:08

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
63.4K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
922